[Skip to Content]
[Skip to Content Landing]

September 2019 - April 2015

Decade

Year

Issue

July 2018, Vol 4, No. 7, Pages 905-1023

Original Investigation

Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):930-937. doi:10.1001/jamaoncol.2017.5597

This propensity score–matched cohort study examines whether adjuvant chemotherapy is associated with improved overall survival in patients with rectal cancer and pathological complete response following neoadjuvant chemoradiation therapy and resection.

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):938-943. doi:10.1001/jamaoncol.2018.0231

This propensity score matching cohort analysis compares the overall survival between adjuvant chemotherapy and postoperative observation in patients with rectal cancer with pathologic complete response following neoadjuvant chemoradiotherapy and resection.

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):944-951. doi:10.1001/jamaoncol.2018.1093

This secondary analysis of a randomized clinical trial assesses the automated Bone Scan Index as an independent prognostic determinant of overall survival in men with metastatic castration-resistant prostate cancer.

Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis

Abstract Full Text
free access has active quiz
JAMA Oncol. 2018;4(7):953-961. doi:10.1001/jamaoncol.2018.1071

This systematic review and meta-analysis examines the association of smoking status with biochemical recurrence, metastasis, and cancer-specific mortality among patients with localized prostate cancer undergoing primary radical prostatectomy or radiotherapy.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):963-969. doi:10.1001/jamaoncol.2018.0329

This single-arm, phase 2 clinical trial evaluates the margin-negative resection rate in borderline-resectable pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) therapy and individualized chemoradiotherapy.

Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer

Abstract Full Text
open access
JAMA Oncol. 2018;4(7):970-976. doi:10.1001/jamaoncol.2018.0991

This multicenter validation study examines the accuracy of a breath test that analyzes volatile organic compounds for the diagnosis of esophagogastric cancer among adults in a curative treatment pathway.

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: A Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(7):977-984. doi:10.1001/jamaoncol.2018.0060

This clinical trial evaluates the use of everolimus combined with endocrine therapy in women with estrogen receptor–positive, human epidermal growth receptor 2–negative advanced breast cancer.

Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(7):e180089. doi:10.1001/jamaoncol.2018.0089

This cohort study evaluates the association of cerebrospinal fluid biomarkers of brain injury with short- and long-term outcomes and genetic polymorphisms in children receiving chemotherapy for acute lymphoblastic leukemia.

Delays in the Publication of Important Clinical Trial Findings in Oncology

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(7):e180264. doi:10.1001/jamaoncol.2018.0264

This review of pharmaceutical company press releases assesses how long it takes for complete data from potentially practice-changing industry-sponsored clinical trials in oncology to be published following the availability of important results.

Brief Report

Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):985-989. doi:10.1001/jamaoncol.2017.3852

This analysis examines the association between metastatic lymph node burden and overall survival in patients with laryngohypopharyngeal cancers.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(7):e173695. doi:10.1001/jamaoncol.2017.3695

This post hoc analysis investigates the prognostic and predictive role of primary tumor location according to BRAF, RAS, and microsatellite instability status in patients with colon cancer.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(7):e173776. doi:10.1001/jamaoncol.2017.3776

This phase1/2 trial evaluates the safety and antitumor activity of ipilimumab in women with recurrent cervical cancer.

Research Letter

Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):993-994. doi:10.1001/jamaoncol.2018.0610

This data analysis examines the fulfillment of postmarketing requirements associated with drugs granted accelerated approval for oncology indications in the past 6 years.

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):994-996. doi:10.1001/jamaoncol.2018.0977

This study estimates the total costs associated with administering chimeric antigen receptor T-cell treatment.

Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):996-998. doi:10.1001/jamaoncol.2018.0818

This study evaluates the efficacy of an alert in the electronic health record to reduce overuse of granulocyte colony-stimulating factor in older patients hospitalized with febrile neutropenia.

Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):998-1001. doi:10.1001/jamaoncol.2018.0352

This study of data from the PROSPR consortium assesses the incidence of and risk factors associated with breast cancer with a poor prognosis after undergoing screening mammography with negative results.

Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non–Small Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):1001-1003. doi:10.1001/jamaoncol.2018.0813

This study analyzes the value of magnetic resonance imaging of the brain for patients with cancers that frequently metastasize to the brain.

Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):1003-1006. doi:10.1001/jamaoncol.2018.1080

This secondary analysis of the PETACC-3 trial examines the association of sex with incidence and severity of chemotherapy-related toxic effects in patients with stage II and III colorectal cancer treated with fluorouracil and leucovorin with or without irinotecan hydrochloride.

Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):1006-1008. doi:10.1001/jamaoncol.2018.1263

This study examines the reliability of predictive markers of CT screening for lung cancer and its association with patient outcomes, including mortality.

US Public Perceptions About Cancer Care Provided by Smaller Hospitals Associated With Large Hospitals Recognized for Specializing in Cancer Care

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):1008-1009. doi:10.1001/jamaoncol.2018.1400

This survey study examines patient expectations about cancer care provided by smaller hospitals associated with larger hospitals recognized for specializing in cancer care.

JAMA Oncology Clinical Challenge

Pink Papules in a Patient With Salivary Duct Carcinoma

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(7):991-992. doi:10.1001/jamaoncol.2017.4853

A 46-year-old man with salivary duct carcinoma of the right parotid gland presented for evaluation of a 3-week history of multiple new pruritic skin lesions on the right chest and endorsed erythematous skin changes within the field of radiation. What is your diagnosis?

Viewpoint

Addressing Financial Barriers to Enrollment in Clinical Trials

Abstract Full Text
JAMA Oncol. 2018;4(7):913-914. doi:10.1001/jamaoncol.2018.0492

This Viewpoint discusses the need to refine existing guidance to clarify the broad acceptability of offering all types of payment to research participants to reduce financial burden for patients.

Thalidomide, Drug Safety, and Off-label Prescribing: Lessons Learned From Celgene’s Settlement

Abstract Full Text
JAMA Oncol. 2018;4(7):915-916. doi:10.1001/jamaoncol.2018.0808

This Viewpoint reviews the Celgene settlement and provides a number of suggestions on how to move forward to address the safety and off-label marketing concerns that were litigated in the case.

Editorial
Invited Commentary

Reliably Quantifying Bone Metastases in Prostate Cancer—Are We Finally There?

Abstract Full Text
JAMA Oncol. 2018;4(7):951-952. doi:10.1001/jamaoncol.2018.1069

Smoking and Death From Prostate Cancer

Abstract Full Text
JAMA Oncol. 2018;4(7):961-962. doi:10.1001/jamaoncol.2018.1070

Characterizing an Ultra–High-Risk Subset of Patients With Hypopharynx and Larynx Cancer: The Power of Lymph Node Burden

Abstract Full Text
JAMA Oncol. 2018;4(7):989-990. doi:10.1001/jamaoncol.2017.3928
JAMA Oncology Patient Page

Biosimilars

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):1023. doi:10.1001/jamaoncol.2018.0999

This Patient Page provides information on biosimilars, medicines that are similar to other cancer medicines called biologics.

Cancer Care Chronicles

Acceptance in the End of Life

Abstract Full Text
JAMA Oncol. 2018;4(7):917-918. doi:10.1001/jamaoncol.2017.4516

In this Cancer Chronicle, an oncologist relates using the insights gained from his own child’s cancer death to guide decision making and help a patient’s family understand the benefit of opting against further therapy.

Poetry and Oncology

Blue Infusion

Abstract Full Text
JAMA Oncol. 2018;4(7):923. doi:10.1001/jamaoncol.2018.0805
Comment & Response

Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome

Abstract Full Text
JAMA Oncol. 2018;4(7):1010. doi:10.1001/jamaoncol.2018.0539

Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome—Reply

Abstract Full Text
JAMA Oncol. 2018;4(7):1010. doi:10.1001/jamaoncol.2018.0545

When You Hear Hoofbeats, Look for Horses, Not Zebras

Abstract Full Text
JAMA Oncol. 2018;4(7):1011. doi:10.1001/jamaoncol.2018.0542

When You Hear Hoofbeats, Look for Horses, Not Zebras—Reply

Abstract Full Text
JAMA Oncol. 2018;4(7):1011-1012. doi:10.1001/jamaoncol.2018.0548

Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2

Abstract Full Text
JAMA Oncol. 2018;4(7):1012. doi:10.1001/jamaoncol.2018.0595

Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2—Reply

Abstract Full Text
JAMA Oncol. 2018;4(7):1012-1013. doi:10.1001/jamaoncol.2018.0616

Improving the Propranolol Treatment of Melanoma

Abstract Full Text
JAMA Oncol. 2018;4(7):1013. doi:10.1001/jamaoncol.2018.0598

Improving the Propranolol Treatment of Melanoma—Reply

Abstract Full Text
JAMA Oncol. 2018;4(7):1013-1014. doi:10.1001/jamaoncol.2018.0619

Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia

Abstract Full Text
JAMA Oncol. 2018;4(7):1014. doi:10.1001/jamaoncol.2018.0674

Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia—Reply

Abstract Full Text
JAMA Oncol. 2018;4(7):1014-1015. doi:10.1001/jamaoncol.2018.0677

Association of Statin Use With Overall and Cancer Survival

Abstract Full Text
JAMA Oncol. 2018;4(7):1015-1016. doi:10.1001/jamaoncol.2018.0733

Association of Statin Use With Overall and Cancer Survival

Abstract Full Text
JAMA Oncol. 2018;4(7):1016. doi:10.1001/jamaoncol.2018.0730

Association of Statin Use With Overall and Cancer Survival—Reply

Abstract Full Text
JAMA Oncol. 2018;4(7):1016-1017. doi:10.1001/jamaoncol.2018.0736

Immune-Related Adverse Events—A Novel Prediction of Nivolumab Efficacy?

Abstract Full Text
JAMA Oncol. 2018;4(7):1017. doi:10.1001/jamaoncol.2018.0745

Immune-Related Adverse Events—A Novel Prediction of Nivolumab Efficacy?—Reply

Abstract Full Text
JAMA Oncol. 2018;4(7):1017-1018. doi:10.1001/jamaoncol.2018.0751
Correction

Incorrect Email Address for Corresponding Author

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):1018. doi:10.1001/jamaoncol.2018.2604
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):910. doi:10.1001/jamaoncol.2017.3234
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(7):905. doi:10.1001/jamaoncol.2017.3233
×